Early research (Phase 1)Study completedNCT01456689What this trial is testingOral LGH447 in Patients With Relapsed and/or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Novartis Pharmaceuticals 79
Very early researchNot Yet RecruitingNCT07539233What this trial is testingA Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.Who this might be right forMultiple Myeloma (MM) Institute of Hematology & Blood Diseases Hospital, China 24
Large-scale testing (Phase 3)Study completedNCT00200681What this trial is testingIFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple MyelomaWho this might be right forMultiple Myeloma Nantes University Hospital 493
Not applicableStudy completedNCT02849444What this trial is testingAssess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine ClearanceWho this might be right forMultiple Myeloma Celgene 326
Very early researchLooking for participantsNCT06045091What this trial is testingTo Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCLWho this might be right forMultiple MyelomaPlasma Cell Leukemia Hrain Biotechnology Co., Ltd. 18
Testing effectiveness (Phase 2)Study completedNCT01602224What this trial is testingTabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)Who this might be right forMultiple Myeloma Eli Lilly and Company 220
Not applicableNot Yet RecruitingNCT07034755What this trial is testingPhase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple MyelomaWho this might be right forMultiple Myeloma (MM)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Chimeric Antigen Receptor T-cell The Affiliated Hospital of Xuzhou Medical University 20
Early research (Phase 1)UnknownNCT03706547What this trial is testingAnti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MMWho this might be right forMultiple Myeloma in RelapseMultiple Myeloma Progression Peng Liu 20
Not applicableUnknownNCT04388735What this trial is testingMultiple Myeloma (MM) Quality of Life (QOL) StudyWho this might be right forMultiple MyelomaQuality of LifeSymptom, Behavioral Massachusetts General Hospital 360
Large-scale testing (Phase 3)Study completedNCT01239797What this trial is testingPhase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaWho this might be right forLymphomaMultiple Myeloma Bristol-Myers Squibb 646
Testing effectiveness (Phase 2)Looking for participantsNCT05632380What this trial is testingASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)Who this might be right forMultiple Myeloma Institute of Hematology & Blood Diseases Hospital, China 20
Early research (Phase 1)Study completedNCT02955550What this trial is testingA Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)Who this might be right forMultiple Myeloma Celularity Incorporated 15
Early research (Phase 1)Looking for participantsNCT07003568What this trial is testingDual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary InfiltrationWho this might be right forRelapsed or Refractory Multiple Myeloma (RRMM) Beijing GoBroad Hospital 18
Not applicableUnknownNCT05218603What this trial is testingEvaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCTWho this might be right forMultiple MyelomaNon-eligible for Autologous Stem Cell Transplantation (ASCT) PETHEMA Foundation 100
Post-approval studies (Phase 4)UnknownNCT02577783What this trial is testingPDD vs PAD to Treat Initially Diagnosed MMWho this might be right forMultiple Myeloma The First Affiliated Hospital of Soochow University 64
Early research (Phase 1)Not Yet RecruitingNCT07735546What this trial is testingUB-VV500 With Rapamycin in Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma in RelapseMultiple Myeloma (MM) Umoja Biopharma 100
Early research (Phase 1)Looking for participantsNCT07003555What this trial is testingDual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary InfiltrationWho this might be right forRelapsed or Refractory Multiple Myeloma (RRMM) Beijing GoBroad Hospital 18
Testing effectiveness (Phase 2)Study completedNCT02185820What this trial is testingPhase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)Who this might be right forMultiple Myeloma European Myeloma Network B.V. 57
Early research (Phase 1)Study completedNCT02431208What this trial is testingAtezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)Who this might be right forMultiple Myeloma Hoffmann-La Roche 85
Not applicableUnknownNCT05439538What this trial is testingSerum NGAL IN Patients With Multiple MyelomaWho this might be right forMultiple Myeloma(MM) Assiut University 60